Cerebrospinal Fluid Proteomic Characterization in Major Depressive Disorder
Session
Pharmaceutical and Natural Sciences
Description
Major depressive disorder (MDD) is a highly prevalent and increasing disease, characterized by low mood, anhedonia, sadness, and guilt. Despite its heterogeneity, neither a biomarker nor a biosignature has been introduced to clinical practice, which would ensure greater diagnostic and prognostic accuracy. The review of the available literature reveals an increase in the number of studies being conducted to better understand the pathophysiologic mechanisms of MDD, as well as the urgent need to develop diagnostic biomarkers. Several molecules are discussed as promising indicators of depressive conditions, that are involved in different processes such as inflammation, structural and transportation molecules, and synaptic transmission. However, to confirm their diagnostic and prognostic value, additional large-scale studies and the application of cutting-edge analytical techniques are required.
Keywords:
major depressive disorder, proteomics, CSF, biomarker.
Proceedings Editor
Edmond Hajrizi
ISBN
978-9951-550-50-5
Location
UBT Kampus, Lipjan
Start Date
29-10-2022 12:00 AM
End Date
30-10-2022 12:00 AM
DOI
10.33107/ubt-ic.2022.100
Recommended Citation
Muqaku, Liridon, "Cerebrospinal Fluid Proteomic Characterization in Major Depressive Disorder" (2022). UBT International Conference. 100.
https://knowledgecenter.ubt-uni.net/conference/2022/all-events/100
Cerebrospinal Fluid Proteomic Characterization in Major Depressive Disorder
UBT Kampus, Lipjan
Major depressive disorder (MDD) is a highly prevalent and increasing disease, characterized by low mood, anhedonia, sadness, and guilt. Despite its heterogeneity, neither a biomarker nor a biosignature has been introduced to clinical practice, which would ensure greater diagnostic and prognostic accuracy. The review of the available literature reveals an increase in the number of studies being conducted to better understand the pathophysiologic mechanisms of MDD, as well as the urgent need to develop diagnostic biomarkers. Several molecules are discussed as promising indicators of depressive conditions, that are involved in different processes such as inflammation, structural and transportation molecules, and synaptic transmission. However, to confirm their diagnostic and prognostic value, additional large-scale studies and the application of cutting-edge analytical techniques are required.